NRG Oncology Appoints NCORP Investigator, Matthew Hudson, as Cancer Care Delivery Research Committee Co-Chair

PHILADELPHIA, PA — NRG Oncology recently appointed Matthew F. Hudson, PhD, MPH as Co-Chair for the organization’s Cancer Care Delivery Research (CCDR) Committee. He joins the present Co-Chair Debra Ritzwoller in the leadership of this committee. Drs. Hudson and Ritzwoller each represent a National Cancer Institute (NCI) Community Oncology Research Program (NCORP) institution. Participating NCORP community sites, like the ones Drs. Hudson and Ritzwoller represent, make cancer research available to larger and more diverse patient populations. Dr. Hudson’s addition to the leadership team may enhance NRG Oncology’s capacity to evolve community-informed research protocols.

Dr. Hudson is co-investigator and Cancer Care Delivery Research Director of NCORP of the Carolinas (an NCORP community site awardee) and the Director of the Greenville Health System’s Office of Human Research Protection. Previously, Dr. Hudson served as an external reviewer of grant applications for the Center for Disease Control and Prevention (CDC) where he became engaged in the challenges underrepresented or priority populations face in traditional care settings. He also served on and later co-chaired NCI’s CCDR Coordinating Committee. He served on the Editorial Board for the Center of Medicare and Medicaid Services (CMS) journal Medicare and Medicaid Research Review, and is presently a member of PCORI’s Merit Review Committee. His service to both clinical and population-based research underscores his commitment to intervening on the social and behavioral factors impacting cancer care for priority populations. His prior and current experience position him to translate these insights to access and policy innovations improving clinical practice and population wellness. Dr. Hudson’s commitment to addressing factors mediating cancer care for underrepresented populations, his aptitude for integrating patient values into health services and health service research, and his dedication to research ethics will strength NRG Oncology’s mission of improving the lives of patients with cancer.

“I am honored to co-chair a committee poised to advance cancer care delivery research at the intersection of multiple pressing challenges. First, we are challenged to clarify clinical and organizational factors mediating evidence-based cancer care. Second, we need to clarify the optimal strategy for helping patients integrate their values and preferences into cancer management, particularly in instances predominated by diagnostic or prognostic uncertainty. Third, our efforts should clarify the social forces mediating appropriate access across the care continuum. This means elucidating para-clinical and environmental factors
enhancing appropriate screening and treatment, and also facilitating appropriate engagement among cancer survivors. Working in an NCORP Site informs me of practical challenges and opportunities investigators should consider in research concept development. I am thrilled to collaborate with investigators on this noble enterprise," stated Dr. Hudson.

NRG Oncology’s NCORP seeks to provide scientific and statistical leadership for developing, implementing, and analyzing multi-institutional clinical trials of cancer prevention, control, screening, and post-treatment surveillance, as well as cancer care delivery research.

www.nrgoncology.org

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the NSABP Foundation, the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located worldwide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.